Ophthalmic Business News

The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release.

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age-related macular degeneration, according to a press release.

As physicians, we have all borne witness to patients dying at a young age, whether from an unforeseen illness or injury.

On this episode, Laura Enyedi, MD, and Dagny Zhu, MD, are live from Eyecelerator discussing the work life balance with guests Rupa Wong, MD, and Carolyn Pan, MD.

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s lead candidate gene therapy for optogenetic vision restoration, according to a press release.

The FDA approved the Zeiss Mel 90 excimer laser for the treatment of myopia, hyperopia and mixed astigmatism, according to a press release.

4D Molecular Therapeutics reported positive interim data from the first part of the SPECTRA clinical trial investigating 4D-150 in patients with diabetic macular edema, according to a press release.